OmniComm Systems, Inc.
Fort Lauderdale, FL, October 8, 2015 – OmniComm Systems, Inc. (OmniComm) (OTCQX: OMCM), a global leading provider of clinical data management technology, announced today that TrialMaster EDC was again selected by a leading biopharmaceutical company as the platform for a large, long-term global patient disease registry. Additionally, OmniComm’s Transformation Services team will perform another large data migration from a legacy platform leveraging the proprietary OmniAdvance™ methodology.
TrialMaster was selected for its inherent flexibility and broad capabilities to support a wide variety of late phase clinical studies including patient registries. OmniComm’s significant expertise and proven success with studies and patient registries, of all sizes and disease categories, was of significant importance in their selection criteria.
“This selection brings significant value to all parties – OmniComm, our sponsor, the investigator sites, and most importantly the patients, who benefit from the important rare disease research,” said Ken Light, EVP of transformation services, OmniComm Systems. “The fact that this sponsor has once again entrusted OmniComm as their EDC partner for large disease registries, is a testament to the rich set of EDC system functionality, along with the resources and methodology we will employ to design, build, migrate, and deploy this long-term, global registry.”
Data migration services are delivered by OmniComm Transformation Services, providing professional services that have demonstrated delivery success spanning data migration, integration, data standards, risk-based monitoring, process optimization, and business intelligence.
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.